Ozmosi | Landogrozumab Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Landogrozumab

Alternative Names: landogrozumab, ly2495655
Clinical Status: Inactive
Latest Update: 2020-09-15
Latest Update Note: News Article

Product Description

Mechanisms of Action: GDF8 Inhibitor

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Eli Lilly
Company Location: Eastern America
Company CEO: David A. Ricks
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Landogrozumab

Countries in Clinic: Japan

Active Clinical Trial Count: 1

Recent & Upcoming Milestones

Highest Development Phases

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

JapicCTI-121851

JapicCTI-121851

P2

Active

Unknown

None